Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATE: GenSci004 in Pediatric GHD
NCT06024967Phase 3Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of peg-somatropin in growth hormone deficiency (GHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06024967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024967.